Biofrontera (BFRI)

• Market cap: $7.58M
• 1 day: -4.07%
• 5 days: -2.15%
• 1 month: 25.46%
• 3 months: -23.55%
• 6 months: -5.00%
• Year to date: -65.05%
• 1 year: -71.22%
• 5 years: -98.89%
• 10 years: -98.89%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.

Employees: 85

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

36% more capital invested

Capital invested by funds: $1.05M [Q2] → $1.43M (+$377K) [Q3]

3.61% less ownership

Funds ownership: 22.97% [Q2] → 19.36% (-3.61%) [Q3]

25% less funds holding

Funds holding: 12 [Q2] → 9 (-3) [Q3]

75% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 4

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 5

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $7 615% upside
• Avg. target: $7 615% upside
• High target: $7 615% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Benchmark Bruce Jackson 45% 1-year accuracy 24 / 53 met price target

615% upside $7

Buy Reiterated

15 Nov 2024